Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma

1. Hutson, T.E.
2. Escudier, B.
3. Esteban, E.
4. Bjarnason, G.A.
5. Lim, H.Y.
6. Pittman, K.B.
7. Senico, P.
8. Niethammer, A.
9. Lu, D.R.
10. Hariharan, S.
11. Motzer, R.J.